- Home
- Publications
- Publication Search
- Publication Details
Title
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 55, Issue 2, Pages 263-269
Publisher
Informa UK Limited
Online
2013-05-09
DOI
10.3109/10428194.2013.803226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
- (2012) A. Wiestner BLOOD
- Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
- (2012) M. S. Davids et al. BLOOD
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- IgM Amyloidosis: Clinical Features in Therapeutic Outcomes
- (2012) Morie A. Gertz et al. Clinical Lymphoma Myeloma & Leukemia
- Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints
- (2012) Jonathan Hsu et al. IMMUNOLOGY LETTERS
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
- (2012) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Meeting the Decision-Making Preferences of Patients With Breast Cancer in Oncology Consultations: Impact on Decision-Related Outcomes
- (2012) Richard Brown et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme
- (2011) Onima Chowdhury et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2011) P. C. Amrein et al. CLINICAL CANCER RESEARCH
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
- (2011) Víctor Quesada et al. NATURE GENETICS
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia
- (2010) W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
- (2008) G. Lenz et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started